The Role of Management Guidelines in Formulary Decision-Making and Recent Lp(a) Recommendations

EP: 1.Lp(a) in ASCVD and Guideline Recommendations

EP: 2.Introduction and Burden of Atherosclerotic Disease and Aortic Stenosis

EP: 3.The Role of Prevention in the Management of Atherosclerotic Disease and Aortic Stenosis

EP: 4.Studying the Association Between Elevated Lp(a) Levels and Risk of Atherosclerotic Disease

EP: 5.Lp(a) Levels: A Continuous Relationship With ASCVD Levels and Consistent Throughout a Lifetime

EP: 6.How the Genetic Nature of Lp(a) Levels Influences Screening

EP: 7.A Case Study of Elevated Lp(a) Levels and Increased ASCVD Risk

Now Viewing

EP: 8.The Role of Management Guidelines in Formulary Decision-Making and Recent Lp(a) Recommendations

EP: 9.Evidence Supporting 2024 Guidance for Lp(a) Testing

Video content above is prompted by the following:

• How do guideline recommendations factor into formulary decisions about preventive measures like Lp(a) testing?
• In the introduction, I mentioned that there are several national and international guidelines offering slightly different recommendations about when Lp(a) should be measured. Among these are statements from the American Association of Clinical Endocrinologists and American College of Endocrinology, the American Heart Association, and the American College of Cardiology from 2022 or earlier, which recommend Lp(a) measurement in patients with a family history of atherosclerotic cardiovascular disease and/or elevated Lp(a) levels. However, in 2024, the NLA recommended that Lp(a) be measured in all adults. How does this recommendation align with recent guidance from Europe and Canada?